News | Artificial Intelligence | November 26, 2020

Study conducted by medical AI startup Lunit and Massachusetts General Hospital, published in JAMA Network Open - When used as a second reader, the AI algorithm may help detect lung cancer

Study conducted by medical AI startup Lunit and Massachusetts General Hospital, published in JAMA Network Open - When used as a second reader, the AI algorithm may help detect lung cancer

November 26, 2020 — A recent study published in JAMA Network Open has shown that an AI algorithm trained to detect pulmonary nodules can improve lung cancer detection on chest radiographs.

The study was conducted by MGH and Lunit, a South Korean medical artificial intelligence (AI) company. The joint research team analyzed 5,485 chest radiographs collected from participants in the National Lung Screening Trial (NLST) with Lunit INSIGHT CXR, an AI software for diagnosing chest x-rays.

According to this diagnostic study, the sensitivity and specificity of the AI algorithm for finding malignant pulmonary nodules were 94% and 83%, respectively. It even had a higher sensitivity compared to NLST radiologists, implementing its possibility to help detect lung cancer when used as a second reader.

“Low-dose CT is recommended for lung cancer screening because the detection of chest radiographs is challenging for radiologists due to its projectional nature of radiography,” explained Subba Digumarthy, the senior author of the study and an attending thoracic radiologist at MGH. “However, compared with chest radiography, CT is less accessible and more expensive, exposing patients to a higher dose of radiation. This study shows that AI can provide diagnostic value to more patients by supplementing the shortcomings and maintaining the advantages of x-ray diagnosis.”

“Through this first collaboration with the MGH research team, we are happy to validate the generalizability and accuracy of our AI approach based on NLST data,” said Brandon Suh, CEO of Lunit. “It is a meaningful study to show Lunit INSIGHT CXR can be utilized to diagnose cancer-related nodules and detect lung cancer in earlier stages.”

Lunit Insight CXR analyzes more than 3 million images in more than 80 countries, and has an accuracy of 97 to 99% in detecting 10 major chest diseases such as lung nodules and pneumothorax. It is CE marked and clinically available in Europe.

For more information: www.lunit.io


Related Content

News | Cardiac Imaging

May 21, 2026 — A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s ...

Time May 22, 2026
arrow
News | X-Ray

May 21, 2026 — RADIN Health and AZmed have announced the expansion of their strategic partnership and enhance radiology ...

Time May 22, 2026
arrow
News | Digital Pathology

May 7, 2026 — Roche has entered into a definitive merger agreement to acquire PathAI, a U.S.-based company in digital ...

Time May 21, 2026
arrow
News | Computed Tomography (CT)

May 12, 2026 – Bracco Imaging S.p.A. has purchased a mobile photon-counting CT scanner from MARS Bioimaging to support ...

Time May 20, 2026
arrow
Feature | Enterprise Imaging | Kyle Hardner

For radiology departments, the imbalance between surging imaging volume and a shortage of trained radiologists is taking ...

Time May 20, 2026
arrow
News | Interventional Radiology

May 12, 2026 — Siemens Healthineers has received clearance from the Food and Drug Administration for six new systems in ...

Time May 12, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

May 11, 2026 – At the International Society for Magnetic Resonance in Medicine (ISMRM) 2026 Annual Meeting, GE ...

Time May 11, 2026
arrow
News | FDA

May 6, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer ...

Time May 07, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

April 27, 2026 — SimonMed, one of the nation’s largest independent outpatient imaging providers, has announced the ...

Time May 04, 2026
arrow
News | Computed Tomography (CT)

April 23, 2026 — Royal Philips has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ...

Time April 30, 2026
arrow
Subscribe Now